|
| Product Name: | Vecuronium bromide | | Synonyms: | norcuron;[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetoxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-(1-piperidyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate;1-[(2Beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl]-1-methylpiperidinium bromide hydrate;1-(3-alpha,17-beta-diacetoxy-2-beta-piperidino-5-alpha-androstan-piperidiniu;17beta-diol,16beta-pipecolinio-2beta-piperidino-5alpha-androstan-3alphbro;mide,diacetate;nc-45;orgnc45 | | CAS: | 50700-72-6 | | MF: | C34H57BrN2O4 | | MW: | 637.73138 | | EINECS: | 256-723-9 | | Product Categories: | CAMPRAL;API;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Steroid and Hormone;Pharmaceutical material and intermeidates;Organics;Neuromuscular blocking agent;Steroids;Acetylcholine receptor;APIs;50700-72-6 | | Mol File: | 50700-72-6.mol |  |
| | Vecuronium bromide Chemical Properties |
| Melting point | 227-229°C | | alpha | +30.5～+35.0゜(D/20℃)(c=0.5,dil.HCl) | | storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | Slightly soluble in water, freely soluble in methylene chloride, sparingly soluble in acetonitrile and in anhydrous ethanol. | | form | neat | | color | White | | Merck | 14,9941 | | BRN | 4837308 | | Stability: | Hygroscopic | | InChIKey | VEPSYABRBFXYIB-PWXDFCLTSA-M | | CAS DataBase Reference | 50700-72-6(CAS DataBase Reference) |
| Hazard Codes | Xi,Xn | | Risk Statements | 36/37/38-22 | | Safety Statements | 26-37/39 | | WGK Germany | 3 | | RTECS | TN4875000 | | HS Code | 2933399090 | | Toxicity | LD50 in mice: 0.061 mg/kg i.v. (Buckett) |
| | Vecuronium bromide Usage And Synthesis |
| Description | Vecuronium bromide (Brand name: Norcuron) is a drug which can be supplied to general anesthesia to keep skeletal muscle relaxation during the surgery or mechanical ventilation. It can also be used to help with endotracheal intubation. It has rapid onset (within 4 minutes) and has its effect last for 4 hour. Its mechanism of action is through competitively binding to the nicotinic cholinergic receptors, further antagonizing the opportunity for acetylcholine from binding to the nicotinic receptor at the postjunctional membrane of the myoneural junction. This process prevents the depolarization and the release of calcium ions, stopping muscle contraction and help muscle relaxation.
| | References | https://en.wikipedia.org/wiki/Vecuronium_bromide
https://www.drugbank.ca/drugs/DB01339
| | Description | Vecuronium, 1-[(2β,3α,5α,16β,17β,)-3,17-bis(acetyloxy)-2-(1-piperidinyl)
androstan-16-yl]-1-methylpiperidinium bromide (15.1.9), differs from panuronium only in
the extent of alkylation. Only the piperidine substituent on C16 of the steroid skeleton is
transformed into a quaternary salt. | | Description | Vecuronium is a non-depolarizing muscle relaxant derived from the aminosteroid pancuronium and used adjunctively to general anesthesia. It competitively blocks cholinergic receptors at the motor end plate of the neuromuscular junction, inducing temporary paralysis. In humans, it has been shown to reduce muscle twitch tension with an ED50 value of 0.15 mg/kg for a duration of 27 minutes without inducing cardiovascular effects. | | Chemical Properties | White Solid | | Uses | alcohol antagonist | | Uses | An aminosteroid, competitive neuromuscular blocker agent. | | Definition | ChEBI: The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium su
stituents. | | Brand name | Norcuron (Organon). | | Biological Functions | Vecuronium bromide (Norcuron) is chemically
identical to pancuronium except for a tertiary amine in
place of a quaternary nitrogen. However, some of the
drug will exist as the bisquaternary compound, depending
on body pH. Vecuronium has a moderate onset of
action (2.4 minutes) and a duration of effect of about 50
minutes. Like pancuronium, it does not block ganglia or
vagal neuroeffector junctions, does not release histamine,
and is eliminated by urinary excretion. | | General Description | Vecuronium bromide, 1-(3 ,17 -dihydroxy-2 -piperidino-5 -androstan-16 -yl)-1-methylpiperidinium bromide diacetate (Norcuron), is themonoquaternary analog of pancuronium bromide. It belongsto the class of nondepolarizing neuromuscular blockingagents and produces effects similar to those of drugs in thisclass. It is unstable in the presence of acids and undergoesgradual hydrolysis of its ester functions in aqueous solution.Aqueous solutions have a pH of about 4.0. | | Pharmacology | Vecuronium bromide is steroidal agent that was developed in an attempt to
reduce the cardiovascular effects of pancuronium. I t is similar in structure to
the older drug, differing only in the loss of a methyl group from one
quaternary ammonium radical. Thus it is a monoquaternary amine. An intubating dose of 0.1mgkg-1 produces profound neuromuscular block
within 3min. This dose produces clinical block for about 30min. Vecuronium
rarely produces histamine release, nor does it have any direct cardiovascular
effects, although it allows the cardiac effects of other anaesthetic agents, such as bradycardia produced by the opioids, to go unchallenged. Vecuronium is
excreted through the kidneys (30%), although to a lesser extent than
pancuronium, and undergoes hepatic deacetylation; the deacetylated
metabolites have neuromuscular blocking properties. Repeated doses should
be used with care in patients with renal or hepatic disease because they
accumulate. | | Clinical Use | Vecuronium Bromide is usedmainly to produce skeletal muscle relaxation during surgeryand to assist in controlled respiration after general anesthesiahas been induced. | | Veterinary Drugs and Treatments | Vecuronium is indicated as an adjunct to general anesthesia to produce
muscle relaxation during surgical procedures or mechanical
ventilation and to facilitate endotracheal intubation. It causes very
minimal cardiac effects and generally does not cause the release of
histamine. | | Drug interactions | Potentially hazardous interactions with other drugs
Anaesthetics: enhanced muscle relaxant effect.
Anti-arrhythmics: procainamide enhances muscle
relaxant effect.
Antibacterials: effect enhanced by aminoglycosides,
clindamycin, polymyxins and piperacillin.
Antiepileptics: muscle relaxant effects antagonised by
carbamazepine; effects reduced by long-term use of
fosphenytoin and phenytoin but might be increased
by acute use.
Botulinum toxin: neuromuscular block enhanced
(risk of toxicity). | | Metabolism | Vecuronium partly metabolised by the liver; the metabolites have some neuromuscular blocking activity. It is excreted mainly in bile as unchanged drug and metabolites; some is also excreted in the urine. |
| | Vecuronium bromide Preparation Products And Raw materials |
|
